FUSN
Fusion Pharmaceuticals Inc

632
Loading...
Loading...
News
all
press releases
Acquisition of Fusion Pharmaceuticals Completed
Acquisition of Fusion Pharmaceuticals Completed Acquisition of Fusion Pharmaceuticals Completed PR Newswire HAMILTON, ON and BOSTON, June 4, 2024 HAMILTON, ONandBOSTON, June 4, 2024 /PRNewswire...
PR Newswire·1y ago
News Placeholder
More News
News Placeholder
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement PR Newswire HAMILTON, ON and BOSTON, May 31, 2024...
PR Newswire·1y ago
News Placeholder
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca PR Newswire HAMILTON, ON and BOSTON, May 29, 2024...
PR Newswire·1y ago
News Placeholder
Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake
Bloomberg / Contributor / Getty Images Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...
Investopedia Headlines·1y ago
News Placeholder
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN PR Newswire NEW YORK, May 13, 2024 NEW...
PR Newswire·1y ago
News Placeholder
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN PR Newswire NEW YORK, May 10, 2024 NEW YORK, May 10...
PR Newswire·1y ago
News Placeholder
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Fusion Pharmaceuticals...
PR Newswire·1y ago
News Placeholder
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Fusion Pharmaceuticals Inc. (NasdaqGS: FUSN) to...
Business Wire·1y ago
News Placeholder
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical...
PR Newswire·1y ago
News Placeholder
Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm
Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, April 26, 2024 NEW YORK...
PR Newswire·1y ago

Latest FUSN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.